MARKETS / NASDAQ / PLSM
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Pulsenmore Ltd. PLSM

3 fiscal years on record · ILS · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
ILS 40.0M
▲ 314.3% vs FY2024
EPS · FY25
ILS 2.46
Dividend / sh · FY25
Payout · FY25
ROE · FY25
Net margin · FY25
-39.6%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
ILS 40.0M
Revenue, FY2025 · full 3-year series below
Revenue Net income
0.020.040.060.0-0.020232025
0.020.040.060.0-0.020232025

The company lost 40 cents on every revenue dollar this year.

Per share
ILS 2.46
Diluted EPS, FY2025
EPS
48122.4620232025
48122.4620232025

The company pays no cash dividend.

Profitability
Return on equity, FY2025
ROE
0.250.50.75120232025
0.250.50.75120232025
Operating margin
Net margin-39.6%
Return on assets-13.0%

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base
Shares outstanding, FY2025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
ILS 101.8M
total assets, end of FY2025
Total assetsILS 101.8M
CashILS 21.6M
Current ratio7.88×

History
3 fiscal years
Every figure from documents filed with the SEC · ILS
Metric
2025
2024
2023
Revenue ILS B
0.0
0.0
0.0
Operating income ILS B
·
·
·
EBITDA ILS B
·
·
·
Income tax ILS B
0.0
−0.0
0.0
Net income ILS B
−0.0
−0.0
−0.1
EPS, diluted ILS
2.46
5.76
9.12
Dividend / sh ILS
·
·
·
Payout %
·
·
·
ROE %
·
·
·
Shares out B
·
·
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
10 of 10
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed